Combination of hypomethylating agents and inhibitor of BCL-2 in treatment of patients with relapsed acute myeloid leukemia: S.P. Botkin hospital experience

[1]  T. Duong,et al.  Venetoclax combination therapy in relapsed/refractory acute myeloid leukemia: A single institution experience. , 2020, Leukemia research.

[2]  M. Tallman,et al.  Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: a systematic review and meta-analysis. , 2020, Haematologica.

[3]  D. Pollyea,et al.  How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia , 2019, Leukemia.

[4]  A. Letai,et al.  Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. , 2019, Blood.

[5]  G. Marcucci,et al.  Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia , 2018, Haematologica.

[6]  M. Konopleva,et al.  Clinical experience with the BCL2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies , 2018, American journal of hematology.

[7]  Bob Löwenberg,et al.  Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. , 2017, Blood.

[8]  J. Tchinda,et al.  Changes in cytogenetics and molecular genetics in acute myeloid leukemia from childhood to adult age groups , 2016, Cancer.

[9]  Bob Löwenberg,et al.  Resistance Prediction in AML: Analysis of 4,601 Patients from MRC/NCRI, HOVON/SAKK, SWOG, and MD Anderson Cancer Center , 2014, Leukemia.

[10]  James M. Bogenberger,et al.  BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies , 2014, Leukemia.

[11]  K. Coombes,et al.  Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells , 2012, Annals of Hematology.

[12]  H. Gundacker,et al.  Age and acute myeloid leukemia. , 2006, Blood.

[13]  A. Venditti,et al.  Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML). , 2003, Blood.

[14]  V. Doronin,et al.  Azacitidine/Venetoclax Combination as First-Line Therapy in Elderly Patients with Acute Myeloid Leukemias: A First Step , 2022, Clinical oncohematology.

[15]  OUP accepted manuscript , 2021, Japanese Journal Of Clinical Oncology.